Reckitt Benckiser To Acquire Adams Respiratory (ARXT) for $60/Share
Reckitt Benckiser Group plc and Adams Respiratory Therapeutics (Nasdaq: ARXT) entered into a definitive agreement under which Reckitt Benckiser will tender for the acquisition of Adams for $60 per share in cash, representing a total consideration for Adams' fully diluted share capital of approximately $2.3 billion.
The transaction will be financed by Reckitt Benckiser by cash on hand and existing credit facilities.
Shares of Adams Respiratory closed at $43.68 on Friday.
The transaction will be financed by Reckitt Benckiser by cash on hand and existing credit facilities.
Shares of Adams Respiratory closed at $43.68 on Friday.
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- Barclays on Cooper (CBE)/Eaton (ETN) Deal: Industry Implications - Is Hubbell (HUB-B) Up Next?
- Rhoen-Klinkum to recommend Fresenius (FMS) takeover offer -Bloomberg
Create E-mail Alert Related Categories
Hot List, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
